banner
03
August
2016

Major progress towards orthopaedics approvals: Tissue Regenix is now in the commercialisation phase having validated its dCELL® technology to produce 'like-for-like' tissue specific, structure-preserving scaffolds for use in multiple clinical settings. DermaPure has started well in the US for treating chronic wounds and traction will increase now that it is widely reimbursed by Medicare providers. But newsflow in the next 12 months is likely to be dominated by the approval and launch of the orthopaedics products for meniscal and tendon repairs. Despite short term monthly cashburn of c., TRX is building long term value, evidenced by 32p NPV driven by three core product areas.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/tissue-regenix--documents/03-08-16-major-progress-towards-ort...

Read more from this release

Medical technology created in York closer to global brand status following German joint venture

27
Jan
2016
www.yorkpress.co.uk

Regenix hits sales landmark for wound treatment

21
Jan
2016
www.yorkshirepost.co.uk